^
Association details:
| Biomarker: | KRAS G12C + STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Krazati (adagrasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
99O_PR - KRYSTAL-1: Activity and Preliminary Pharmacodynamic (PD) Analysis of Adagrasib (MRTX849) in Patients (Pts) With Advanced Non–Small- Cell Lung Cancer (NSCLC) Harboring KRASG12C Mutation
Published date:
03/17/2021
Excerpt:
KRYSTAL-1 (NCT03785249) is a multi-cohort phase I/II study evaluating adagrasib in pts with advanced or metastatic solid tumors, including NSCLC, harboring a KRASG12C mutation....79 pts with pre-treated NSCLC were treated with adagrasib 600 mg BID (phase I/Ib and phase II)….In a subpopulation of pts with STK11-comutations, ORR was 64% (9/14).
Trial ID:
